Article
Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
The FEBS journal - 1 Dec 2020
Song Kai, Lu Haibo, Jin Liangliang, Wang Kai, Guo Wenbing, Zheng Hailong, Li Keru, He Chuchu, You Tianyi, Fu Yelin, Yang Jing, Zhao Wenyuan, Guo Zheng
Abstract excerpt
Cetuximab therapy, which heavily relies on the activation of Ras pathway, has been used in KRAS, NRAS, BRAF, and PIK3CA wild-type colorectal cancer (CRC) (Ras-normal). However, the response rate only reached 60%, due to false-negative mutation detection and mutation-like transcriptome features in wild-type patients. Herein, by integrating RNA-seq, microarray, and mutation data, we developed a Ras pathway...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.